Sustainable Solutions for Patients' Sake
(6/30, Blasine Penkowski, National Pharmaceutical Council: E.V.I.dently Today) comments “...As we seek broader dialogue about these questions, NPC will continue to convene stakeholders in settings such as the Going Below The Surface Forum. Our conversations will help clarify how to transform health care stakeholders' positive actions – bright spots amid the crisis – into sustainable improvements for patients: As indicated by the fact that during the pandemic many access hurdles have come down, there's broad recognition that they impede care. Barriers to patient access should continue to fall. We should encourage developments that bring broader and more efficient access to care, such as the growth of telehealth.” Full
Comparing Diabetes Therapies in Patients with Low versus Increased CV Risk
(6/30, Patrick Campbell, HCP Live) reports “Despite the excitement surrounding the multiple classes of glucose-lowering therapies for diabetes management, results of a new systematic review and network meta-analysis suggest there was no difference in outcomes based on treatment in drug-naive patients at low cardiovascular risk.” Full
With Low Heart Risk in T2D, Choose Metformin First
(6/29, Kristen Monaco, Medpage Today) reports “...‘To facilitate more robust and consistent NMAs for comparative effectiveness research that can inform individualized care, clinical trials should attempt to enroll a more heterogeneous patient population that includes the full range of cardiovascular risk and diabetes duration and should try to categorize these factors similarly,’ [Christine Lee, MD, MS and William Cefalu, MD] suggested.” Full
COVID-19 and the New Pragmatism
(6/30, Paul Bridges, Biopharma Dive) comments “...COVID-19 is raising questions about the impact of traditionally conservative regulatory thinking on drug development. Regulators, exercising greater pragmatism, are showing new interest in RWE and post-marketing surveillance. RWE also presents an opportunity to identify treatments for further study earlier, accelerate drug development, and leverage synthetic control arms. In other words, regulators appear to be moving from being risk-averse about RWE to prudently enthusiastic.” Full
Will COVID-19 Be Evidence-Based Medicine's Nemesis?
(6/30, Trisha Greenhalgh, PLOS Medicine) comments “...In the current fast-moving pandemic, where the cost of inaction is counted in the grim mortality figures announced daily, implementing new policy interventions in the absence of randomized trial evidence has become both a scientific and moral imperative. Whilst it is hard to predict anything in real time, history will one day tell us whether adherence to ‘evidence-based practice’ helped or hindered the public health response to Covid-19—or whether an apparent slackening of standards to accommodate ‘practice-based evidence’ was ultimately a more effective strategy.” Full
Top Democrat Dropping Support for Previously Bipartisan Senate Drug Pricing Effort
(6/29, Peter Sullivan, The Hill) reports “...Sen. Ron Wyden (Ore.), the top Democrat on the Senate Finance Committee, will not co-sponsor an updated version of what had been a bipartisan measure to lower drug prices, as his partnership with Sen. Chuck Grassley (R-Iowa) on the issue appeared to fall apart on Monday...Grassley said Democrats, led by Senate Minority Leader Charles Schumer (D-N.Y.), were walking away from the negotiations to preserve drug pricing as a campaign issue, while Wyden said Republicans were never really at the table to begin with given that Senate Majority Leader Mitch McConnell (R-Ky.) does not support the bill.” Full
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Apostolos Tsapas, MD, MSc (Oxon), PhD, et al.
June 30, 2020, Annals of Internal Medicine
Annals of Internal Medicine
Tisagenlecleucel Versus Historical Standard Therapies for Pediatric Relapsed/refractory Acute Lymphoblastic Leukemia
Qiufei Ma, et al.
June 30, 2020, Journal of Comparative Effectiveness Research
Journal of Comparative Effectiveness Research